Levetiracetam Tablet, Film Coated
Product Images NDC 70518-1108

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-1108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a prescription medication (marked RX ONLY) with the name "levETIRAcetam" in the form of 500mg tablets. It comes in a package of 30 tablets and the NDC number is 70518-1108-00. It should be kept out of reach of children and should be stored between 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F) [See USP]. The manufacturer is Lupin Pharma located in Baltimore, MD 21202 and the medication was repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.465.8762. The Lot number and Expiry dates are not available.*
FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01
This text provides a formula to calculate the total daily dose of medication in milliliters for a patient based on their weight and the daily dose in milligrams per kilogram. The medication concentration is given as 100 mg/mL.*
FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02
This is a formula used to calculate CLer, which is the renal clearance of creatinine. The formula takes into account the patient's age, weight, and serum creatinine level. The result of CLer is then adjusted for the patient's body surface area (BSA). It is likely used by medical professionals to determine kidney function in patients.*
FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04
This appears to be a table displaying percentages related to two groups, one being administered 1000mg/day and the other 3000mg/day of Levetiracetam. The top row shows values ranging from 45% to 0%. The left column shows labels for each of the percentage values displayed. The meaning of the percentages cannot be determined without additional context.*
FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05
This appears to be a table showing the percentages of patients in a study taking different dosages of levetiracetam and a placebo, with the number of patients in each group listed in parentheses. However, without more context or information, it is difficult to provide further details or conclusions about the study.*
FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07
This appears to be a table of data showing the percentage of patients in two different groups - one group taking a placebo (with a sample size of 7) and the other group taking levetiracetam (with a sample size of 101). It is not clear what the percentages represent, as some cells only contain symbols or are cut off. Without additional context, it is difficult to provide a more specific description.*
FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08
This text seems to be showing the percentage of patients who received either a placebo or Levetiracetam, with the corresponding number of patients in each group. The placebo group had 51 patients and 19.6% of them responded to treatment, while the Levetiracetam group had 58 patients and 43.1% of them responded to treatment.*
FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09
This appears to be a graph or chart showing the percentage of patients in a study who had varying levels of response to a placebo and the medication levetiracetam, with the number of patients in each group noted in parentheses. The x-axis shows percentages ranging from 0% to 100%, while the y-axis lists the two groups being compared. However, the graph itself is not available to further interpret the data.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.